Literature DB >> 8821592

Mechanisms of hyperproduction of TEM-1 beta-lactamase by clinical isolates of Escherichia coli.

P J Wu1, K Shannon, I Phillips.   

Abstract

The mechanisms of hyperproduction (defined as > or = 200 nmoles nitrocefin hydrolysed per minute per mg of protein) of TEM-1 beta-lactamase by 38 isolates of Escherichia coli were investigated. The copy numbers of TEM-encoding plasmids were determined for the hyperproducing isolates and for 39 TEM-1-producing isolates that did not hyperproduce the enzyme. Allele-specific PCR was used to determine if the promoter region of the TEM-1 gene was of the TEM-1 or TEM-2 type. Twenty three of the 38 hyperproducers had the TEM-1-type promoter but 15 had the more efficient TEM-2-type promoter; in contrast, 37 of the 39 isolates with lower activities had the TEM-1-type promoter and only two had the TEM-2-type promoter. Many of the TEM-1-hyperproducing isolates possessed small plasmids (< or = 20 MDal) with high copy numbers, in some cases together with large, low copy number plasmids; the average total copy number of TEM-encoding plasmids was 14; if only isolates with the TEM-1-type promoter were included, average total copy number was 22. Hyperproduction was attributed to high copy number (> or = 10) plasmids in 11 isolates; another seven had plasmids with moderately high copy numbers (4-9). The average total copy number for isolates that produced relatively small amounts of TEM-1 beta-lactamase (< or = 100 nmoles/min/mg protein) was 2.2, and for the 12 isolates with TEM-1 activities of 101-200 nmoles/min/mg protein it was 6.8. We conclude that both high copy number plasmids and a more efficient promoter are common causes of hyperproduction of TEM-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8821592     DOI: 10.1093/jac/36.6.927

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group.

Authors:  C De Champs; D Sirot; C Chanal; R Bonnet; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Diversity of TEM mutants in Proteus mirabilis.

Authors:  R Bonnet; C De Champs; D Sirot; C Chanal; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital.

Authors:  C Chanal; R Bonnet; C De Champs; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 4.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 5.  Antimicrobial resistance in Haemophilus influenzae.

Authors:  Stephen Tristram; Michael R Jacobs; Peter C Appelbaum
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

6.  Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.

Authors:  Mohammad Faheem; Md Tabish Rehman; Mohd Danishuddin; Asad U Khan
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

7.  Molecular Analysis of Antibiotic Resistance Determinants and Plasmids in Malaysian Isolates of Multidrug Resistant Klebsiella pneumoniae.

Authors:  Farah Al-Marzooq; Mohd Yasim Mohd Yusof; Sun Tee Tay
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

8.  Antimicrobial resistance of Klebsiella pneumoniae stool isolates circulating in Kenya.

Authors:  Chris Rowe Taitt; Tomasz A Leski; Daniel P Erwin; Elizabeth A Odundo; Nancy C Kipkemoi; Janet N Ndonye; Ronald K Kirera; Abigael N Ombogo; Judd L Walson; Patricia B Pavlinac; Christine Hulseberg; Gary J Vora
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

9.  Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.

Authors:  A Oliver; M Pérez-Vázquez; M Martínez-Ferrer; F Baquero; L De Rafael; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

10.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.